Literature DB >> 11696612

Functional properties of human nicotinic AChRs expressed by IMR-32 neuroblastoma cells resemble those of alpha3beta4 AChRs expressed in permanently transfected HEK cells.

M E Nelson1, F Wang, A Kuryatov, C H Choi, V Gerzanich, J Lindstrom.   

Abstract

We characterized the functional and molecular properties of nicotinic acetylcholine receptors (AChRs) expressed by IMR-32, a human neuroblastoma cell line, and compared them to human alpha3 AChRs expressed in stably transfected human embryonic kidney (HEK) cells. IMR-32 cells, like neurons of autonomic ganglia, have been shown to express alpha3, alpha5, alpha7, beta2, and beta4 AChR subunits. From these subunits, several types of alpha3 AChRs as well as homomeric alpha7 AChRs could be formed. However, as we show, the properties of functional AChRs in these cells overwhelmingly reflect alpha3beta4 AChRs. alpha7 AChR function was not detected, yet we estimate that there are 70% as many surface alpha7 AChRs in IMR-32 when compared with alpha3 AChRs. Agonist potencies (EC(50) values) followed the rank order of 1,1-dimethyl-4-phenylpiperazinium (DMPP; 16+/-1 microM) > nicotine (Nic; 48 +/- 7 microM) > or = cytisine (Cyt; 57 +/- 3 microM) = acetylcholine (ACh; 59 +/- 6 microM). All agonists exhibited efficacies of at least 80% relative to ACh. The currents showed strong inward rectification and desensitized at a rate of 3 s(-1) (300 microM ACh; -60 mV). Assays that used mAbs confirmed the predominance of alpha3- and beta4-containing AChRs in IMR-32 cells. Although 18% of total alpha3 AChRs contained beta2 subunits, no beta2 subunit was detected on the cell surface. Chronic Nic incubation increased the amount of total, but not surface alpha3beta2 AChRs in IMR-32 cells. Nic incubation and reduced culture temperature increased total and surface AChRs in alpha3beta2 transfected HEK cells. Characterization of various alpha3 AChRs expressed in HEK cell lines revealed that the functional properties of the alpha3beta4 cell line best matched those found for IMR-32 cells. The rank order of agonist potencies (EC(50) values) for this line was DMPP (14 +/- 1 microM) = Cyt (18 +/- 1 microM) > Nic (56 +/- 15 microM > ACh (79 +/- 8 microM). The efficacies of both Cyt and DMPP were approximately 80% when compared with ACh and the desensitization rate was 2 s(-1). These data show that even with the potential to express several human nicotinic AChR subtypes, the functional properties of AChRs expressed by IMR-32 are completely attributable to alpha3beta4 AChRs.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11696612      PMCID: PMC2233843          DOI: 10.1085/jgp.118.5.563

Source DB:  PubMed          Journal:  J Gen Physiol        ISSN: 0022-1295            Impact factor:   4.086


  37 in total

1.  Acetylcholine receptor extracellular domain determines sensitivity to nicotine-induced inactivation.

Authors:  A Kuryatov; F A Olale; C Choi; J Lindstrom
Journal:  Eur J Pharmacol       Date:  2000-03-30       Impact factor: 4.432

2.  Multiorgan autonomic dysfunction in mice lacking the beta2 and the beta4 subunits of neuronal nicotinic acetylcholine receptors.

Authors:  W Xu; A Orr-Urtreger; F Nigro; S Gelber; C B Sutcliffe; D Armstrong; J W Patrick; L W Role; A L Beaudet; M De Biasi
Journal:  J Neurosci       Date:  1999-11-01       Impact factor: 6.167

3.  High efficiency fusion procedure for producing monoclonal antibodies against weak immunogens.

Authors:  R D Lane; R S Crissman; S Ginn
Journal:  Methods Enzymol       Date:  1986       Impact factor: 1.600

4.  Definition of a continuous human cell line derived from neuroblastoma.

Authors:  J J Tumilowicz; W W Nichols; J J Cholon; A E Greene
Journal:  Cancer Res       Date:  1970-08       Impact factor: 12.701

5.  Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches.

Authors:  O P Hamill; A Marty; E Neher; B Sakmann; F J Sigworth
Journal:  Pflugers Arch       Date:  1981-08       Impact factor: 3.657

6.  Altered baroreflex responses in alpha7 deficient mice.

Authors:  D Franceschini; A Orr-Urtreger; W Yu; L Y Mackey; R A Bond; D Armstrong; J W Patrick; A L Beaudet; M De Biasi
Journal:  Behav Brain Res       Date:  2000-08       Impact factor: 3.332

7.  Up-regulation of cell-surface alpha4beta2 neuronal nicotinic receptors by lower temperature and expression of chimeric subunits.

Authors:  S T Cooper; P C Harkness; E R Baker; N S Millar
Journal:  J Biol Chem       Date:  1999-09-17       Impact factor: 5.157

8.  Characterization of bovine and human neuronal nicotinic acetylcholine receptors using monoclonal antibodies.

Authors:  P J Whiting; J M Lindstrom
Journal:  J Neurosci       Date:  1988-09       Impact factor: 6.167

9.  Coordinate morphological and biochemical interconversion of human neuroblastoma cells.

Authors:  R A Ross; B A Spengler; J L Biedler
Journal:  J Natl Cancer Inst       Date:  1983-10       Impact factor: 13.506

10.  The relationship of the postsynaptic 43K protein to acetylcholine receptors in receptor clusters isolated from cultured rat myotubes.

Authors:  R J Bloch; S C Froehner
Journal:  J Cell Biol       Date:  1987-03       Impact factor: 10.539

View more
  22 in total

1.  Nerve terminal nicotinic acetylcholine receptors initiate quantal GABA release from perisomatic interneurons by activating axonal T-type (Cav3) Ca²⁺ channels and Ca²⁺ release from stores.

Authors:  Ai-Hui Tang; Miranda A Karson; Daniel A Nagode; J Michael McIntosh; Victor N Uebele; John J Renger; Matthias Klugmann; Teresa A Milner; Bradley E Alger
Journal:  J Neurosci       Date:  2011-09-21       Impact factor: 6.167

2.  Negative allosteric modulators that target human alpha4beta2 neuronal nicotinic receptors.

Authors:  Brandon J Henderson; Ryan E Pavlovicz; Jerad D Allen; Tatiana F González-Cestari; Crina M Orac; Andrew B Bonnell; Michael X Zhu; R Thomas Boyd; Chenglong Li; Stephen C Bergmeier; Dennis B McKay
Journal:  J Pharmacol Exp Ther       Date:  2010-06-15       Impact factor: 4.030

3.  Modulation of recombinant, α2*, α3* or α4*-nicotinic acetylcholine receptor (nAChR) function by nAChR β3 subunits.

Authors:  Bhagirathi Dash; Minoti Bhakta; Yongchang Chang; Ronald J Lukas
Journal:  J Neurochem       Date:  2012-03-14       Impact factor: 5.372

4.  Selective deletion of the alpha5 subunit differentially affects somatic-dendritic versus axonally targeted nicotinic ACh receptors in mouse.

Authors:  Harald Fischer; Avi Orr-Urtreger; Lorna W Role; Sigismund Huck
Journal:  J Physiol       Date:  2004-12-20       Impact factor: 5.182

5.  Characterization of ganglionic acetylcholine receptor autoantibodies.

Authors:  Steven Vernino; Jon Lindstrom; Steve Hopkins; Zhengbei Wang; Phillip A Low
Journal:  J Neuroimmunol       Date:  2008-05-15       Impact factor: 3.478

6.  Biochemical and functional properties of distinct nicotinic acetylcholine receptors in the superior cervical ganglion of mice with targeted deletions of nAChR subunit genes.

Authors:  Reinhard David; Anna Ciuraszkiewicz; Xenia Simeone; Avi Orr-Urtreger; Roger L Papke; J M McIntosh; Sigismund Huck; Petra Scholze
Journal:  Eur J Neurosci       Date:  2010-03-03       Impact factor: 3.386

7.  Pharmacological and immunochemical characterization of alpha2* nicotinic acetylcholine receptors (nAChRs) in mouse brain.

Authors:  Paul Whiteaker; Jennifer A Wilking; Robert W B Brown; Robert J Brennan; Allan C Collins; Jon M Lindstrom; Jim Boulter
Journal:  Acta Pharmacol Sin       Date:  2009-06       Impact factor: 6.150

8.  Heterogeneity of nicotinic acetylcholine receptor expression in the caudal nucleus of the solitary tract.

Authors:  David V Smith; Victor V Uteshev
Journal:  Neuropharmacology       Date:  2007-11-05       Impact factor: 5.250

9.  Autoimmune autonomic ganglionopathy: IgG effects on ganglionic acetylcholine receptor current.

Authors:  Z Wang; P A Low; J Jordan; R Freeman; C H Gibbons; C Schroeder; P Sandroni; S Vernino
Journal:  Neurology       Date:  2007-05-29       Impact factor: 9.910

10.  Immunization with neuronal nicotinic acetylcholine receptor induces neurological autoimmune disease.

Authors:  Vanda A Lennon; Leonid G Ermilov; Joseph H Szurszewski; Steven Vernino
Journal:  J Clin Invest       Date:  2003-03       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.